Biomarin Pharmaceutical
๐จ๐ฆCanada
- Country
- ๐จ๐ฆCanada
- Ownership
- -
- Established
- 1997-01-01
- Employees
- -
- Market Cap
- $17.2B
- Website
- http://www.biomarin.com
Sapropterin Expanded Access Program
- Conditions
- First Posted Date
- 2007-06-12
- Last Posted Date
- 2008-04-15
- Lead Sponsor
- BioMarin Pharmaceutical
- Registration Number
- NCT00484991
A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT00445978
A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 190
- Registration Number
- NCT00403494
Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-07-21
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 12
- Registration Number
- NCT00355264
Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 111
- Registration Number
- NCT00332189
A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-05-15
- Last Posted Date
- 2009-07-21
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 84
- Registration Number
- NCT00325962
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 4
- Registration Number
- NCT00299000
- Locations
- ๐ต๐น
Hospital PediAtrico de Coimbra, Coimbra, Portugal
๐บ๐ธChildren's Hospital Oakland, Oakland, California, United States
๐ซ๐ทHospital Femme Mere Enfant Centre, Lyon, France
Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 45
- Registration Number
- NCT00272792
A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2009-08-20
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 100
- Registration Number
- NCT00225615
Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)
Completed
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- BioMarin Pharmaceutical
- Target Recruit Count
- 237
- Registration Number
- NCT00214773
- Locations
- ๐บ๐ธ
Emory University, Decatur, Georgia, United States
๐บ๐ธAnn and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
๐บ๐ธFullerton Genetic Center, Asheville, North Carolina, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath